Share
Cellf Bio reported implantation of its autologous bioengineered sphincter in Phase I clinical trial for patients with faecal incontinence. Credit: fizkes via Shutterstock.com.

Arrowhead Pharmaceuticals has completed enrolment of subjects for its Phase III PALISADE trial of ARO-APOC3 to treat familial chylomicronemia syndrome (FCS), an ultrarare genetic disease often caused by various monogenic mutations.

The international AROAPOC3-3001 PALISADE trial will assess the investigational RNAi therapeutic ARO-APOC3’s efficacy and safety in adult subjects with FCS.

Related Company Profiles

View all

Percent change from baseline in fasting triglycerides (TG) at month ten is the trial’s primary endpoint.

For this trial, 75 subjects were distributed across 39 different sites in 18 countries and randomised to receive 25mg and 50mg doses of ARO-APOC3, or matching placebos, once every three months.

After completing the randomised period, participants will be eligible for continuing in a two-part extension period and will receive ARO-APOC3.

See Also:

The primary portion of the clinical trial is expected to be completed in the second quarter of next year, with a data readout shortly thereafter and subsequent submissions of applications for regulatory review and approval.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Arrowhead Pharmaceuticals chief medical officer Javier San Martin said: “Completing enrolment of the Phase III PALISADE study represents a significant milestone for Arrowhead and brings our potentially important RNAi-based medicines closer to the patients that may benefit from them.

“I am grateful to the FCS patient community and principal investigators for their trust and participation in the PALISADE study.”

The company is developing ARO-APOC3 as a treatment for patients with mixed dyslipidemia, severe hypertriglyceridemia, and FCS.

Extremely high triglyceride levels due to FCS can lead to different serious signs and symptoms, including chronic abdominal pain, acute and potentially fatal pancreatitis, and type 2 diabetes mellitus, among others.

In July last year, Arrowhead dosed the first subjects in two Phase I/IIa clinical trials of pulmonary candidates, ARO-MUC5AC and ARO-RAGE, to potentially treat various muco-obstructive and inflammatory pulmonary diseases, respectively.